# A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

> **NCT04508621** · PHASE3 · COMPLETED · sponsor: **Tonix Pharmaceuticals, Inc.** · enrollment: 514 (actual)

## Conditions studied

- Fibromyalgia

## Interventions

- **DRUG:** TNX-102 SL
- **DRUG:** Placebo SL Tablet

## Key facts

- **NCT ID:** NCT04508621
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-22
- **Primary completion:** 2021-11-01
- **Final completion:** 2021-11-01
- **Target enrollment:** 514 (ACTUAL)
- **Last updated:** 2023-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04508621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04508621, "A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04508621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*